Avastin Decision Leaves Lingering Uncertainty As To Threshold Level Of Progression-Free Survival Benefit

In her memo revoking Avastin’s metastatic breast cancer claim, FDA Commissioner Hamburg declines to adopt a “bright-line” cutoff of median PFS improvement that would be necessary to establish efficacy, despite industry’s desire for more certainty about the threshold for approval.